The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraven House Capital Regulatory News (CRV)

Share Price Information for Craven House Capital (CRV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.20
Bid: 0.15
Ask: 0.25
Change: 0.00 (0.00%)
Spread: 0.10 (66.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.20
CRV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Year-end Update and Financial Calendar

3 Jul 2019 12:24

RNS Number : 3825E
Craven House Capital PLC
03 July 2019
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Craven House Capital plc

 

("Craven House" or the "Company")

 

Year-end Update and Financial Calendar

 

Craven House Capital (AIM:CRV) is pleased to announce the following unaudited year-end investment update covering the year ending 31 May 2019.

 

Highlights

 

· Directors estimate that Net Asset Value ("NAV") per share has increased by 17% to $9.99 per share in the six-month period from November 2018 to May 2019.

 

· Changes in valuations reflect the previously announced repositioning of capital allocation and current investment focus in North America.

 

The table below sets out the latest estimate of the appropriate carrying value of the Company's investments as at 31 May 2019 in comparison to the values as of the latest published financial statements of the Company.

 

 

Investment

Estimated value at 31 May 19

(unaudited)

Value at 30 Nov 18 (unaudited)

 

 

 

Shares in Craven Industrial Holdings Plc

$27,605,161

$23,892,006

 

Comprising:

 

 

Shares in DLC Holdings Corp.

$8,757,041

$6,491,893

 Shares in Qeton Ltd

$650,206

$1,551,814

Shares in Craven House Angola LDA

$7,921,212

$8,903,150

Shares in Craven House Capital North America LLC

$7,907,782

$4,528,396

Shares in Kwikbuild Corporation Ltd

$2,368,919

$2,416,753

 

 

Portfolio update

 

The valuation of the Company's shareholding in Craven Industrial Holdings Plc ("CIH"), its principal wholly-owned investment holding company, has increased from $23.9m to $27.6m. This reflects the change in the respective value of subsidiary holdings as follows;

 

 

DLC Holdings Corp. (TSXV:DLC) - 68% owned by CRV

 

DLC is a Toronto Stock Exchange listed agricultural investment company with holdings in Brazil and South Africa. The valuation ascribed to CIH's shareholding in DLC in CRV's financial statements reflects the latest published share price of DLC's shares as of 31 May multiplied by the number of shares owned by CIH.

 

The valuation of DLC has increased due to an increase in the share price of DLC between Nov 18 and May 19.

 

 

Qeton Ltd ("Qeton") - 50% owned by CRV.

 

Qeton Ltd is a joint venture company focusing on the distribution of mobile phones, tablet computers and accessories into emerging markets.

 

The valuation of Qeton during the past six-month period has reduced from $1.55m to $0.650m reflecting a reduction in the earnings of Qeton during the period, with shares in Qeton valued at a multiple to net earnings based on the prior 12 months of trading. Whilst earnings have reduced, Qeton remains profitable and has a positive trading outlook.

 

 

Craven House Angola LDA ("CHA") - 100% owned by CRV.

 

Craven House Angola continued to provide local currency financing to Angolan subsidiaries of US and European companies in the consumer electronic and energy sectors. The carrying value of CHA's loan portfolio reduced from $8.9m to $7.9m during the six-month period to May 2019, reflecting the repayment of a portion of the outstanding loan facilities, in accordance with the terms of repayment. The proceeds of the repayments were passed to the parent company and utilized for general working capital purposes and for investment into Craven House's North American subsidiary.

 

Craven House Capital North America LLC ("CHNA") - 100% owned by CRV

 

The valuation of Craven's US investment holding company, CHNA, increased from $4.5m to $7.9m during the six months to May 2019. The majority of this increase reflects the successful sale of CHNA's wholly owned insurance business to LM Funding America Inc. ("LMFA") a NASDAQ listed entity as announced in January 2019. As of May 2019, CHNA owns c.25% of the common shares of LMFA and holds c.$3.6m in convertible notes in LMFA. CHNA also benefits from an equity portfolio valued at c.$3.5m, on a mark-to-market basis, as of May 2019.

 

 

 Kwikbuild Corporation Ltd. - 97% owned by CRV

 

There was little change in the valuation of Kwikbuild during the six-month period to the end of May 2019. The slight reduction in carrying value is the result of exchange rate movements and operating costs; the valuation of the underlying South African assets remained unchanged during this period. We continue with the process of liquidating our remaining holdings in South Africa.

 

 

Net Asset Value

 

As of the end of May 2019 the Directors estimate that the combined value of the other assets and liabilities of the Company represent a total liability of c.$2.6m. Of total liabilities of c.$3.6m, the majority (c.$2.4m) comprise intercompany loans or are due to related parties.

 

The approximate Net Asset Value of the Company therefore stood at c.$25.0m as of May 2019, equating to an NAV per share of $9.99 (vs. $8.57 as of November 2018). This estimate is prior to calculation of any performance fees due to the Investment Manager, which will be finalized following completion of the year-end audit.

 

Share buyback Update

 

The High Court has approved the reduction in share capital which is now subject to final formalities before being completed.

 

Financial Calendar

 

In order to provide shareholders with more regular information regarding the Company's investments, the Directors have decided to amend Craven House's reporting cycle to include, in addition to its interim and preliminary results, two further portfolio updates. These portfolio updates will occur shortly after the May year-end and November interim period in July and December respectively. This RNS forms the first of these new portfolio updates.

 

Going forward, the Company intends to follow the below financial timetable:

 

Anticipated date

Portfolio and NAV update

July

Preliminary financial results (for previous financial year)

Sept / Oct

Portfolio and NAV update

December

Interim Results

March

 

In addition to the above financial reporting calendar the Company will, in accordance with its obligations under the AIM Rules for Companies, make additional updates of matters which it considers appropriate. This may or may not include additional NAV updates.

 

 

 

~ Ends ~

 

 

For further information please contact:

 

Craven House Capital Plc

Mark Pajak

www.Cravenhousecapital.com

 

Tel: 0203 286 8130

 

 

SI Capital

Broker

Nick Emerson

www.sicapital.co.uk

Tel: 01483 413500

 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis/Mark Brady

www.Sparkadvisorypartners.com

 

Tel: 0203 368 3550

 

 

 

About Craven House Capital:

 

The Company's Investing Policy is to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets globally in any geographic jurisdiction. The company will invest in both developed and developing markets providing long term patient capital and is often involved in special situations, restructuring, expansion and turn around investments in crisis and transitioning economies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGUUPMUPBGGW
Date   Source Headline
26th Sep 20072:00 pmRNSTrading Statement
10th Aug 20077:01 amRNSAIM Rule 26
21st Jun 20077:01 amRNSJoint Venture
19th Jun 20073:52 pmRNSIssue of Warrants
14th Jun 200711:37 amRNSResult of AGM
14th Jun 20077:01 amRNSAGM Statement
31st May 20071:00 pmRNSTotal Voting Rights
31st May 200712:30 pmRNSIssue of Equity
31st May 200712:00 pmRNSRelated Party Transactions
25th Apr 20072:42 pmRNSTrading Update
11th Apr 200711:20 amRNSHolding(s) in Company
22nd Mar 20077:02 amRNSFinal Results
19th Mar 20078:00 amRNSNotice of Results
11th Dec 200611:51 amRNSTotal Voting Rights
26th Oct 20067:01 amRNSProperty Development
27th Sep 20067:01 amRNSInterim Results
31st Jul 20067:01 amRNSSaga Contract
10th Jul 20067:00 amRNSItalian Contract Update
4th Jul 200610:58 amRNSChange of Adviser
16th Jun 20064:13 pmRNSResult of AGM
16th Jun 20067:00 amRNSAGM Statement
17th May 20067:00 amRNSReport and Accounts Posted
25th Apr 20062:48 pmRNSProgress in First Quarter
6th Apr 20066:24 pmRNSDirector/PDMR Shareholding
6th Apr 20068:00 amRNSPreliminary Results
22nd Feb 20063:46 pmRNSShare price movement
16th Dec 200512:25 pmRNSChange of Registered Office
23rd Nov 20057:00 amRNSExpansion into Cyprus, Turkey
28th Oct 20058:00 amRNSBusiness Update
29th Sep 20054:47 pmRNSInterim Results
4th Jul 20057:00 amRNSProperty Development
15th Jun 200511:00 amRNSAGM Statement
20th May 200512:59 pmRNSAnnual Report and Accounts
16th May 20059:00 amRNSBusiness Update
21st Apr 200512:42 pmRNSTrading Statement
21st Mar 20059:38 amRNSFinal Results
3rd Mar 20054:39 pmRNSNotice of Prelimnary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.